Mr. Gallagher, MBA, CFA, is an accomplished healthcare and capital markets executive and investor with a distinguished record of success in both the public and private markets. He has over 25 years of life-science experience on Wall Street and in industry. Mr. Gallagher serves as Managing Director of Laidlaw Venture Partners and Senior Managing Director and head of healthcare institutional sales at Laidlaw & Co. (UK) Ltd. Pat is CEO of Voltron Therapeutics, which is developing a novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. He also is CEO of PD Theranostics, which is optimizing and standardizing its proprietary prognostic imaging workflows and predictive artificial intelligence (AI) algorithms to enhance existing pathology results and provide predictive data designed to drive clinical decisions. Mr. Gallagher serves as a strategic consultant for Athenex, Inc., a biopharmaceutical firm focused on next-generation therapies in oncology and immunology. He also is treasurer of AerWave Medical and sits on the board of directors at Algorithm Sciences, Cingulate Therapeutics, and Evermore Global Advisors, a global money manager. Mr. Gallagher co-founded BDR Research Group, LLC, an independent sell-side research firm specializing in healthcare investing, financing and operations, and served as its chief executive officer.

Luba Greenwood is a distinguished executive, investor, and company builder with over 20 years of leadership in healthcare and technology, and extensive global board experience. She is the CEO of Gallop Oncology, a clinical stage biotech. She has founded and served as Managing Partner of Dana Farber Cancer Institute venture fund, and CEO and board chair of multiple life sciences companies including Kojin Tx. She is an Entrepreneur-in-Residence at PureTech, where she plays a key role in advancing oncology programs. Luba has a proven track record of building world-class teams and companies, leading over $15B in deals and investments across therapeutics, diagnostics, and life sciences globally. She has held leadership roles at Google (Verily) and Roche, where as VP of Global Business Development & M&A, she spearheaded diagnostics BD and established the East Coast Innovation Hub. Recognized as an industry thought leader, she advises CEOs of top academic institutions, including Dana-Farber Cancer Institute and Wyss Center. She serves on the Investor Committee for National Cancer Institute and contributes to NEJM Catalyst. Luba is a strategic leader in digital transformation, AI, M&A, financing, and governance, with expertise in scaling companies, guiding high-impact transactions, and driving innovation at the intersection of biotech and technology. A former lawyer at WilmerHale, Luba is an expert in regulatory, IP, and corporate law. She has served as a Harvard University lecturer and sits on multiple public and private boards, including In8Bio, BenchSci, Stalicla, Abcam (where she led its sale to Danaher), Closed Loop Medicine, and MassBio.

Dr. Azadeh Khanicheh is the President and Co-Founder of EnVision Endoscopy, a medical device startup based in Lowell, MA developing novel devices to address the clinical needs for endoscopic surgeries. EnVision Endoscopy is the recipient of NSF SBIR award, and recently closed a SEED round to advance the development of a novel image guided suturing device for endoscopic procedures. Dr. Khanicheh is one of the inaugural awardees of the MLSC’s Massachusetts Next Generation Initiative (MassNextGen) initiatives and participated in MassCONNECT program. Dr. Khanicheh has over a decade of experience in design, development, and launch of innovative medical devices, and served different technical lead engineering positions at PENTAX Medical, BD Medical, and Helbing Technik. She led multiple innovation programs on different portfolios of medical devices and evaluated new technologies during this period. She has worked very closely with commercial and marketing experts in the medical device industry. The teams she has led in the past have brought several products from conception through to commercial launch. Dr. Khanicheh has a Ph.D. in Mechanical and Biomedical Engineering and developed one of the first fMRI compatible devices during her tenure at Northeastern University and MGH/HST Martinos Center for Biomedical Imaging.

Dr. Elizabeth O'Day is the CEO and Founder of Olaris, Inc., a precision medicine company that uses a pioneering metabolomics platform and proprietary machine learning algorithms to fundamentally improve how disease is diagnosed and treated. Olaris identifies “biomarkers of response” (BoR) to stratify patients into optimal treatment groups, increasing survival rates, decreasing adverse events, and reducing unnecessary healthcare costs. Dr. O’Day serves on the Personalized Medicine Coalition (PMC) Board of Directors. In this role, Dr. O’Day collaborates with stakeholders across academia, industry, and government to increase access to personalized medicine. Dr. O’Day also supports the next generation of scientists as adjunct faculty at Boston College, where she taught metabolism and entrepreneurship. Dr. O’Day was recognized by Boston Business Journal as a 40 under 40 honoree in 2020. She is also on the Steering Committee and a contributor for Scientific American's annual "Top 10 Emerging Technologies". During her graduate and undergraduate studies, Dr. O’Day received many of the most prestigious research awards for her personal scientific accomplishments. She earned her Ph.D. from Harvard University, where she was a National Science Fellow; an MPhil in Chemistry from the University of Cambridge where she was a Churchill Fellow; and a BS in Biochemistry from Boston College where she was a Finnegan Award winner, Beckman Scholar, and Goldwater Scholar.